APRIL 25 - 29, 2009
HILTON NEW YORK

PRE-REGISTRATION DEADLINE
MARCH 13, 2009

www.aatod.org
Dear Colleagues, Patients, Advocates, Stakeholders and Friends:

On behalf of the American Association for the Treatment of Opioid Dependence, Inc. (AATOD), and our hosts, the New York State Office of Alcoholism and Substance Abuse Services (OASAS) and COMPA – New York State’s Opioid Treatment Coalition, it is my great pleasure to invite and encourage you to register for the 2009 AATOD Conference. The conference will convene April 25-29, 2009 at the Hilton Hotel in New York City. AATOD Conferences have always been premier training events for treatment providers, public policy makers and advocates from all over the world. AATOD 2009 will be no exception. As you read through this registration brochure, you will find that our planning committee has prepared five days of electric, creative and important programming. As AATOD celebrates its twenty-fifth anniversary, the conference returns to New York City, where methadone maintenance treatment was first developed and expanded. Our conference theme, “Treatment and Recovery: People and Outcomes” places increased focus on where we began, our patients, their recovery and program outcomes. Our conference program gives consistent substance to this theme throughout the plenary sessions, workshops, posters and hot topic roundtables.

AATOD has always been dedicated to providing an outstanding conference experience full of opportunities that will help clinicians deliver quality care with dignity and respect to patients, while providing a forum for discussion and debate on the challenges that face programs, policy makers, advocates and patients. In New York City, we invited key policy and recovery leaders to inform, and help develop consensus on the difficult public policy issues we face, to proclaim the importance and joy of recovery from substance dependence and to inspire and challenge our thinking for the future. Our workshops, posters and hot topics have been selected to engage you in the discussion, to use your ideas and thoughts, to focus you on exciting and innovative projects and to continue to address the special needs of our treatment system. Pre-conference sessions will provide more in-depth focus on stigma, risk, and advocacy and provide basic knowledge for new practitioners. The 2009 Conference will continue AATOD’s mission of building quality treatment programs while educating government officials, program clinicians and administrators, and stakeholders. The always elegant Awards Banquet will honor those dedicated individuals who have made significant contributions and highlight why our field is so special.

The 2009 Conference is also replete with opportunities to interface with your colleagues from all over the world, and to engage federal and state government policy makers, treatment advocates and stakeholders in an effort develop agreement on the many issues before us. From the open AATOD Board Meeting on Saturday, April 25, 2009 to the closing Plenary session on Wednesday, April 29, 2009, you will be an active participant in the dynamic conference schedule. Our planners have worked hard to ensure a diverse and fascinating program. Our exhibit booths will introduce you to the latest in technology, science and products that support our work. The pre-conference activities, welcome reception, breakfasts and refreshment breaks allow for more informal discourse with colleagues, presenters, exhibitors, federal and state officials. AATOD Conferences are always exciting but we have worked hard to ensure that 2009 in New York will be a truly memorable event.

Of course, New York City is a great backdrop for our conference. Our Hospitality Committee is hard at work to make sure you enjoy the sights and sounds of the City, with museums, Times Square and Fifth Avenue shopping just steps away. I urge you to register now.

Warm regards to all,

Ira J. Marion, MA
2009 Conference Chair
## Conference at a Glance

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>April 25</td>
<td></td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 5:00 PM</td>
<td>The Certified Methadone Advocate (CMA) Training Course</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 5:30 PM</td>
<td>Buprenorphine and Office-Based Treatment of Opioid Dependence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:30 AM – 5:00 PM</td>
<td>Performance Improvement in Opioid Treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:00 PM – 5:00 PM</td>
<td>The Physician Clinical Support System</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5:00 PM – 8:30 PM</td>
<td>AATOD Open Board Meeting</td>
</tr>
<tr>
<td>Sunday</td>
<td>April 26</td>
<td>7:30 AM – 7:30 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 5:30 PM</td>
<td>Opioid Maintenance Pharmacotherapy: A Course for Clinicians</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:30 AM – 12:30 PM</td>
<td>Countering Opioid Stigma: Communicating Messages to Influence Public Perception</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:00 AM – 12:00 PM</td>
<td>Opioid Treatment Program Accreditation Town Hall Meeting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:00 AM – 5:30 PM</td>
<td>State Methadone Authorities’ Meeting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:30 AM – 12:00 PM</td>
<td>Opioid Analgesics and Pain in Opioid Dependence Treatment - New Research Findings, Clinical Implications</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>Risk Management in the OTP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>Hepatitis Education for Opioid Treatment Providers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>Trends and Changes in the Quality Framework Called “Accreditation”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>European Opiate Addiction Treatment Association (EUROPAD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2:00 PM – 5:00 PM</td>
<td>Exhibit Hours</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5:30 PM – 7:30 PM</td>
<td>Welcome Reception</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 PM – 8:30 PM</td>
<td>Methadone Anonymous Meeting (Open)</td>
</tr>
<tr>
<td>Monday</td>
<td>April 27</td>
<td>7:30 AM – 7:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 8:30 AM</td>
<td>Continental Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 4:30 PM</td>
<td>Exhibits</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 4:30 PM</td>
<td>Posters in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:45 AM – 10:15 AM</td>
<td>Opening Plenary Session - Meeting Challenges in Turbulent Times: New York State’s Transformed Treatment System and Continuum of Care</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10:30 AM – 12:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:00 PM – 1:30 PM</td>
<td>Lunch (on your own)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 3:00 PM</td>
<td>Workshop Session/Hot Topic Round Tables</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:00 PM – 4:00 PM</td>
<td>Exhibitors Networking Break in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4:00 PM – 5:30 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6:30 PM – 8:00 PM</td>
<td>Town Hall: A Continuing Community Discussion of How OTPs and the Treatment Community Can Work Together to Prepare for the Next “Service Discontinuity”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:00 PM – 8:30 PM</td>
<td>Methadone Anonymous Meeting (Open)</td>
</tr>
<tr>
<td>Tuesday</td>
<td>April 28</td>
<td>7:30 AM – 8:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 8:30 AM</td>
<td>Continental Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 8:45 AM</td>
<td>Poster Author Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 1:30 PM</td>
<td>Exhibits</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 1:30 PM</td>
<td>Posters in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:45 AM – 10:15 AM</td>
<td>Middle Plenary Session - Integrating Recovery-Oriented Systems of Care Into Medication Assisted Treatment: People and Outcomes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10:30 AM – 12:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:00 PM – 1:30 PM</td>
<td>Lunch (on your own)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 3:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:00 PM – 9:30 PM</td>
<td>Awards Banquet</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:30 PM – 10:30 PM</td>
<td>Methadone Anonymous Meeting (Open)</td>
</tr>
<tr>
<td>Wednesday</td>
<td>April 29</td>
<td>7:00 AM – 1:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:00 AM – 8:00 AM</td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 9:30 AM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:45 AM – 11:15 AM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11:30 AM – 12:45 PM</td>
<td>Closing Plenary Session - Policy, Programs and People</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 3:30 PM</td>
<td>Clinic Tours</td>
</tr>
</tbody>
</table>

*All events and times listed are subject to change!*
PRE-CONFERENCE SESSIONS  Saturday, April 25, 2009

8:00 AM - 5:00 PM

The Certified Methadone Advocate (CMA) Training Course
Walter Ginter, CMA, National Alliance of Methadone Advocates (NAMA) MARS Project, New York, NY
Joycelyn Woods, MA, National Alliance of Methadone Advocates (NAMA) MARS Project, New York, NY
J. Thomas Payte, MD, Colonial Management Group, LP, Orlando, FL
Nicholas Reuter, MPH, SAMHSA, Rockville, MD
Belinda Greenfield, EdM, CRC, NYS OASAS, Teaneck, NJ
Dana Moulton, MATS, National Alliance of Methadone Advocates (NAMA); MA NAMA, Marlboro, MA
Howard Lotsof, BFA, National Alliance of Methadone Advocates (NAMA); Dora Weiner Foundation, Staten Island, NY
Donna Schoen, CMA, NAMA; LI NAMA, Long Island, NY
Kerry Wolf, ADN, ARM Texas; We Speak Methadone Forum (NAMA), Cedar, TX

The leading advocate organization for methadone, the National Alliance of Methadone Advocates (NAMA), developed this training, believing that professionals, patients and families of patients can come together to work for a better understanding of methadone and medication assisted treatment. Previous trainings have shown that participants – both professionals and patients alike are equally empowered. Therefore we encourage both patients and non-patients to become Certified Methadone Advocates (CMA). This training is designed for non-clinicians and provides a basic understanding of the physiology of addiction and the use of medications to treat it (i.e. methadone and buprenorphine). Regulations at the federal, state and local levels are explained in simple terms for non-policy makers. Participants will come away with the initial tools for basic advocacy to grow and develop into successful advocates. The course involves 8 hours of rigorous training and fulfills the training requirement for Certification as a Methadone Advocate (CMA).

With these goals in mind, the course presentation is constituted as follows:

- **Medication Assisted Treatment** – Basic clinical information about methadone and buprenorphine treatment.
- **Addiction and Methadone** – Current science about addiction in a language understandable to the non-clinician.
- **Regulations and Accreditation** – Current regulations explained by the federal agency that oversees methadone and buprenorphine treatment.
- **State Methadone Authority** – New York State regulations explained by the NY SMA provide a view of working within state systems.
- **Hands On Advocacy** – Basic tools to work as an advocate and how to manage simple issues that advocates are confronted with including educating patients about their rights, handling grievances, legal issues and working within communities to benefit patients and treatment.
- **Advocacy and The Media** – Responding to negative media in newspapers, television, movies etc. and writing response letters and letters to the editor.
- **Systems Advocacy** – Using advocacy to change policy and working within state and federal systems to improve the rights of patients.
- **Advocacy Campaigns** – Developing an advocacy campaign to target an issue or respond to negative and incorrect information about medication assisted treatment.
- **The Certified Methadone Advocate (CMA)** – What is a Certified Methadone Advocate, ethics of advocacy and the mechanism of certification and how it will professionalize those committed to advocacy.

Candidates for certification must register with NAMA prior to the conference. Registration information is available at: www.methadone.org/registration.doc. On-site registration will be between 8AM to 9AM at the NAMA table in the lobby. NAMA cannot guarantee a place to anyone not pre-registered.

There is a separate registration fee of $100.00 for this pre-conference event. The fee includes all materials, 2008/09 membership in NAMA, and the application for CMA. Lunch is not provided.

Sponsored by the National Alliance of Methadone Advocates (NAMA).

Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment and Covidien-Mallinckrodt.
8:00 AM - 5:30 PM

Buprenorphine and Office-Based Treatment of Opioid Dependence

Edwin A. Salsitz, MD, Beth Israel Medical Center, New York, NY
Petros Levounis, MD, The Addiction Institute of New York, St. Luke’s & Roosevelt Hospitals; Columbia University College of Physicians & Surgeons, New York, NY

The presentation is designed to train qualified physicians in dispensing or prescribing specifically approved Schedule III, IV and V narcotic medications for the treatment of opioid addiction in an office-based setting as part of the Drug Abuse Treatment Act (DATA) 2000.

Physicians qualify after completion of not less than eight (8) hours of approved training. This course satisfies the DATA 2000 eight-hour training requirement. Certificates will be provided to each physician who completes the training confirming the eight hours of training. Certificates may be mailed to the Secretary of Health and Human Services along with a Request for Waiver of the special registration requirements defined in the controlled Substances Act.

The goal of this program is to acquire the knowledge and skills needed to provide optimal care to opioid dependent patients.

Topics covered in the program are:

- Overview of opioid dependence: describes the rationale and effectiveness of opioid pharmacotherapy in the treatment of opioid dependence.

- Buprenorphine efficacy and safety: summarizes the literature on the efficacy and safety of buprenorphine treatment.


- Patient selection: describes the essential aspects of assessing and selecting patients appropriate for office-based opioid treatment.

- Clinical use of buprenorphine: describes induction, stabilization and maintenance protocols for treating opioid dependent patients with buprenorphine.

- Non-pharmacological interventions: describes the efficacy, components and role for non-pharmacological treatments for opioid dependence.

- Medical and psychiatric co-morbidities including HIV/AIDS, hepatitis B and C, depression and anxiety found in opioid dependent patients.

- Special treatment populations: describes the management of pain in patients with addictive disorders, and the management of adolescents and pregnant women with opioid dependence.

- Office procedures: describes and be able to apply clinical tools (e.g. treatment contacts, consents and protocols) needed to set up office-based treatment with buprenorphine. Describes the important confidentiality and record keeping requirements for treating opioid dependent patients in office-based settings.

This program is recommended for physicians with experience and/or interest in treating opioid dependence. This program features didactic and case-based small group discussions. It is also recommended for primary care, psychiatric, HIV, pain and addiction medicine physicians.

There is a separate registration fee for this session, please contact ASAM at ASAM.org.

Sponsored by the American Society of Addiction Medicine. Supported by an unrestricted continuing medical educational grant provided by Reckitt Benckiser.

8:30 AM - 5:00 PM

Performance Improvement in Opioid Treatment

Robert A. Johnson, MEd, DB Consulting, Columbia, MO
Brenda Gilliam-Jones, MPA, DB Consulting/Johnson, Bassin and Shaw, Inc., Orlando, FL

Module One - Introduction to the Workshop:
The purpose of this module is to conduct an overview of the workshop and to set the tone for the training by creating a positive environment for discussion and for learning about performance improvement in opioid treatment facilities.

Module Two - What Is Performance Improvement?
The purpose of this module is to conduct an overview of the workshop and to set the tone for the training by creating a positive environment for discussion and for learning about performance improvement in opioid treatment facilities.

Module Three - Developing an Organizational Culture for Performance Improvement

The purpose of this module is to review the type of organizational culture required to plan and implement an effective, comprehensive performance improvement system.
Pre-Conference Sessions  Saturday, April 25, 2009

Saturday, April 25, 2009

Performance Improvement in Opioid Treatment (continued)

Module Four - Using Outcome Studies in PI Programs
The goal of this module is to discuss the benefits and challenges of examining existing outcome studies in the opioid treatment field and to explore how to develop clinic- or program-based OTP outcome studies.

Module Five - The 12 Steps of the Performance Improvement Process
The purpose of this module is to facilitate, review, and discuss the key elements of an effective performance improvement process. The module will also include strategies for addressing some of the challenges organizations encounter in PI programs including data collection and analysis, writing outcome measures, and evaluating plan effectiveness.

Module Six - Planning to Move Forward
The purpose of this session is to bring the participants together to review lessons learned during the training, to discuss how they will apply those lessons in their own organizations, and to develop specific action plans to address performance improvement needs in their organizations.

Module Seven - Workshop Closing Activities
This section of the workshop will include a summary of the day’s training, a review of participant expectations, and completion of participants’ workshop evaluation forms.

Sponsored by the Center for Substance Abuse Treatment.
Sunday, April 26, 2009

8:00 AM - 5:30 PM

Opioid Maintenance Pharmacotherapy: A Course for Clinicians

Laura McNicholas, MD, Philadelphia Veterans Administration Medical Center, Philadelphia, PA
Susan Neshin, MD, JSAS Healthcare, Inc., Asbury Park, NJ
J. Thomas Payte, MD, Colonial Management Group, LP, Orlando, FL
Trusandra Taylor, MD, Philadelphia, PA

This course is recommended for clinicians with experience and/or interest in medication assisted treatment of opioid dependence. This program provides basic and state of the art information. The curriculum is updated to include current consensus guidance for best practice treatment for opioid addiction. Topics include overview of opioid dependence, epidemiology, opioid pharmacology/neurobiology; evidence-based treatment options, patient assessment/selection, special populations, induction and maintenance protocols, pain management, drug to drug interactions, adverse effects, methadone mortality, managing medical/psychiatric problems, drug testing, regulatory issues, an accreditation update, risk management and an overview of buprenorphine.

Participants will receive a comprehensive syllabus with reference and resource materials. The curriculum will include relevant case study discussion with audience participation to facilitate the learning process. To further integrate the educational objectives, participants are encouraged to discuss challenging problems and clinical issues to facilitate understanding of didactic principles.

Four experienced opioid treatment medical directors will conduct the program, focusing on the goal for participants to acquire the essential knowledge and skills necessary to deliver safe and effective medication assisted treatment for patients with opioid dependence.

The $150.00 registration fee includes a morning coffee service, afternoon luncheon and the evening’s welcome reception.

Sponsored by The American Association for the Treatment of Opioid Dependence, Inc. in cooperation with the American Academy of Addiction Psychiatry and the American Osteopathic Academy of Addiction Medicine.

Supported by the National Institute on Drug Abuse.

8:30 AM - 12:30 PM

Countering Opioid Stigma: Communicating Messages to Influence Public Perception

Frank J. Carillo, ECG, Inc., Englewood, NJ
Dan McGill, McGill Consulting, Brooklyn, NY

Opioid treatment programs and patients have historically been the target of negative public opinion and adverse media coverage. This has affected our ability to influence national drug policy, explain the science of opioid addiction and treatment, gain the funding necessary to provide quality treatment to all who require it, and ultimately to operate in the best interests of our patients and communities.

This workshop teaches three key messages specifically designed to counter the stigma and stereotypes deeply embedded in the perception of opioid addiction and medication-assisted treatment (MAT). These messages resulted from a year-long pilot project entitled “Communicating Messages That Achieve Results”. Providers will hear these messages and learn how to communicate them in order to create a positive impact within their communities. The workshop will include Q & A techniques designed to deal with emotionally charged audiences while reinforcing the presenter’s objective.

This is an updated workshop that premiered at the 2006 Atlanta Conference and was repeated by popular demand in San Diego in 2007. MAT advocates using this approach have been very successful, hence another chance to experience this training!

Sponsored by The American Association for the Treatment of Opioid Dependence.

Supported by VistaPharm, Inc.
The Clinical Trials Network (CTN) is an important program of the National Institute on Drug Abuse (NIDA) focused on the design and implementation of clinically relevant studies in the field of drug addiction treatment research. It consists of seventeen geographically diverse “Nodes” centered in key academic institutions, partnering with local Community Treatment Programs (CTPs). Since 1999, CTN has served as NIDA’s primary vehicle for blending the interests of research and practice and improving drug abuse treatment through science. This includes the Prescription Opioid Addiction Treatment Study and other initiatives focused on prescription opioid addiction and chronic pain.

This session will provide an overview of new research findings in addressing opioid analgesic dependence including assessment, co-occurring pain, patient characteristics, and treatment approaches. Furthermore, current state-of-art clinical practice will be presented and discussed with the AATOD audience.

The first presentation (Dr. Roger Weiss and Dr. Jennifer Sharpe Potter, each 20 minutes of presentation and 15 minutes discussion) will show previously unexamined characteristics of individuals presenting specifically for opioid analgesic dependence treatment, including data from the NIDA National Drug Abuse Treatment Clinical Trials Network study, the largest and most comprehensive opioid analgesic dependence treatment study to be conducted thus far.

The second presentation (Dr. Deborah Haller, 30 minutes presentation, 15 minutes of discussion) will highlight the issues facing substance abuse clinicians who are treating opioid dependent patients with chronic non-cancer pain. She will review preliminary data from a treatment study designed to address pain and addiction concurrently, and will raise issues related to the use of methadone vs. buprenorphine vs. commonly abused opioid analgesics such as hydrocodone or oxycodone for treating co-occurring pain and opioid addiction.

The third presentation (Dr. Steven Passik, 30 minutes presentation, 15 minutes of discussion) will describe recent information on how to assess and address aberrant drug taking behaviors during pain management. Furthermore, a detailed description of issues related to pain management in patients with opioid dependence and strategies for how to address this will be presented.

Sponsored by the National Institute on Drug Abuse, the National Drug Abuse Treatment Clinical Trials Network (NIDA/CTN) and the Center for Substance Abuse Treatment (CSAT).

9:00 AM - 12:00 PM

Opioid Treatment Program Accreditation - Town Hall Meeting

Megan Marx, MPA, The Joint Commission, Littleton, CO
Mary Cesare-Murphy, PhD, The Joint Commission, Oakbrook Terrace, IL

This session is designed to be an open forum for Joint Commission accredited programs to discuss accreditation questions, concerns & challenges. Presenters will provide an overview of OTP accreditation to date. Topics expected to be covered include:

- Changes in the scoring & decision making process
- Changes in the CAMBHC – Leadership Chapter
- Wikepedia Project for Behavioral Health Care
- Robust Process Improvement

Presenters will split the two hour presentation time equally, allowing for Q&A throughout the presentation.

Workshop Objectives

At the end of this workshop participants will be able to:

1. Understand changes made in the scoring & accreditation decision making process & how they may affect their program.
2. Understand changes made in the CAMBHC Leadership chapter, & how to implement these changes in their program.
3. Access & use the Wikepedia Project from the Joint Commission website.
4. Discuss robust process improvement & identify where it may apply to their program.

Registration for this workshop is open to all Joint Commission Accredited Treatment Programs. To pre-register for this workshop please contact Megan Marx at 720-348-0672 or mmarx@jointcommission.org.

Sponsored by The Joint Commission.
**PRE-CONFERENCE SESSIONS**

**Sunday, April 26, 2009**

**9:00 AM - 5:30 PM**

**State Methadone Authorities' Meeting**
*(Closed Session for State and Federal Officials)*

Robert Lubran, MS, Center for Substance Abuse Treatment, Rockville, MD
Nicholas Reuter, MPH, Center for Substance Abuse Treatment, Rockville, MD

**State Methadone Authorities**

Center for Substance Abuse Treatment staff and State Methadone Authorities will convene to discuss a variety of topics of interest to both Substance Abuse and Mental Health Services Administration (SAMHSA) and the states.

**Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.**

**1:00 PM - 4:00 PM**

**Risk Management in the OTP**

*Catherine H. O’Neill, JD, Legal Action Center, New York, NY*

Alan Wartenburg, MD, Tufts University, Boston MA; Opioid Treatment Program, Providence VA Medical Center; Providence, RI

Health care risk management programs emerged 30 years ago and were specifically developed as loss prevention techniques for the risks associated with accidental losses facing health care organizations. AATOD has concluded that opioid treatment programs can benefit from an effective risk management training program, in ways that are similar to the benefits that have accrued to other health care providers. Accreditation has encouraged individualized patient care and developed opportunities for programs to better organize their administrative structure, further supporting risk management.

This session will introduce OTP administrators to the key elements of a risk management program and how they can be directly applied to OTPs. Attendees will also get the most current information available about leading legal risks to OTP operations in addition to a discussion of some critical court cases that have recently affected OTPs.

Topics to be covered include:
- Risk management basics:
  - What happens to the program when adverse events occur
  - Scope of risk management
  - Common risk identifiers
  - Setting priorities
- Existing and emerging medical, clinical and legal standards of care for OTPs:
  - The role that accreditation, certification, regulatory and clinical practice guidelines play in setting standards of care for OTPs
  - Recent negligence/malpractice lawsuits and related legal developments involving OTPs and their patients
- Developing protective medical, clinical and legal strategies to deal with common legal and liability risks, including:
  - Patient induction, dosing and monitoring issues
  - Impaired driving concerns
  - Assessing and addressing complex needs: patients with co-occurring disorders; continuing substance use; other complicating factors
  - OTPs’ liability for patients’ actions.

**Sponsored by the American Association for the Treatment of Opioid Dependence, Inc.**

**Supported by Substance Abuse Mental Health Service Administration Center for Substance Abuse Treatment.**

**1:00 PM - 5:00 PM**

**Hepatitis Education for Opioid Treatment Providers**

Susan Simon, Hepatitis C Association, Scotch Plains, NJ
Bruce Burkett, Hepatitis C Association, Scotch Plains, NJ
Betsy Ingram-Diver, Hepatitis C Association, Scotch Plains, NJ
Patty Gilbert, Hepatitis C Association, Scotch Plains, NJ
David Fiellin, MD, Yale University School of Medicine, New Haven, CT

Hepatitis C Virus (HCV) is considered the most common blood-borne infection in the United States. There are approximately 5 million people infected. Injection drug use accounts for more than two-thirds of all new infections in the United States. OTPs, needle and syringe exchange programs, and comprehensive risk-modifying educational programs have been shown to be effective in preventing HIV transmission and are likely to be useful for decreasing HCV transmissions.

This updated session will provide the most recent information on hepatitis A, B and C, diagnosis, transmission, risk factors, screening, diagnostic testing, referral, treatment, new drugs in trial, healthy behaviors, counseling issues and barriers to care.

**Sponsored by the American Association for the Treatment of Opioid Dependence, Inc.**

**Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.**
PRE-CONFERENCE SESSIONS  Sunday, April 26, 2009

1:00 PM - 5:00 PM

**Trends and Changes in the Quality Framework called “Accreditation”**

Bettye Harrison, CARF, Tucson, AZ  
Brian Boon, CARF International, Tucson, AZ  
Darren Lehrfeld, CARF International, Tucson, AZ

This session is designed to provide a discussion of the changes occurring in the framework of accreditation. Starting this year, CARF International has reorganized its standards into a model we hope will help CARF-accredited organizations to better meet the demands of the modern health and human services environment. The growing demands of the environment require opioid treatment programs to focus their time and resources on strategies to ensure quality service provision. The reorganization of the CARF Business Practice Standards into the **ASPIRE to Excellence™** model demonstrates CARF’s continued commitment to assisting its accredited organization in navigating this changing environment.

The session will focus on:

- An overview of quality standards
- Trends in the provider environment and standard conformance
- Continuous improvement strategies to position organizations for continued success

Sponsored by the Commission on Accreditation of Rehabilitation Facilities (CARF).

1:00 PM - 5:00 PM

**European Opiate Addiction Treatment Association (EUROPAD): Heroin Addiction and Related Clinical Problems**

Chairmen: Icro Maremmani, MD, Pisa, Italy, EU  
Marc Reisinger, MD, Brussels, Belgium, EU

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>Efficacy of Opioid Agonist Therapy on Psychopathological Symptoms: Methadone vs Buprenorphine</td>
<td>Icro Maremmani (Pisa, Italy, EU)</td>
</tr>
<tr>
<td>1:20</td>
<td>Repressive Strategy Against Liberal Strategy in Treating Heroin Addicts in Russia</td>
<td>Vladimir Mendelevich (Kazan, Russia)</td>
</tr>
<tr>
<td>1:40</td>
<td>Economic Evaluation of Interventions To Treat Opiate Dependence: A Review of the Evidence</td>
<td>Christopher M. Doran (Sydney, Australia)</td>
</tr>
<tr>
<td>2:00</td>
<td>The European Experience Delivering Buprenorphine and Methadone. Comparison Between France and Portugal (regulations, clinical experience, practice)</td>
<td>Pascal Courty (Clermont-Ferrand, France, EU), Luis Patricio (Lisbon, Portugal, EU) and Didier Touzeau (Paris, France, EU)</td>
</tr>
<tr>
<td>2:20</td>
<td>Fundamental Principles and Rules in Treating Heroin Addicts at “Fondation Phenix” in Geneve, Switzerland</td>
<td>Michel Bourquin and Jean-Marie Rossier (Geneve, Switzerland)</td>
</tr>
<tr>
<td>2:40</td>
<td>Economic Evaluation of Interventions To Treat Opiate Dependence: A Review of the Evidence</td>
<td>Christopher M. Doran (Sydney, Australia)</td>
</tr>
<tr>
<td>3:00</td>
<td>What Treatment is Good Treatment? Clinician’s Reflections on Patient Perspectives</td>
<td>Alexander Kantchelov, Tsvetana Stoykova, Orlin Todorov and Alexander Belchev (Sofia, Bulgaria, EU)</td>
</tr>
<tr>
<td>3:20</td>
<td>Heroin Addiction and Mortality</td>
<td>Barbara Lovrecic and Mercedes Lovrecic (Ljubljana, Slovenia, EU)</td>
</tr>
<tr>
<td>3:40</td>
<td>Does a Specific Psychopathology of Heroin Addiction Exist?</td>
<td>Pier Paolo Pani (Cagliari, Italy, EU)</td>
</tr>
<tr>
<td>4:00</td>
<td>Treating Heroin Addicts in Jail</td>
<td>Andrej Kastelic (Ljubljana, Slovenia, EU)</td>
</tr>
<tr>
<td>4:20</td>
<td>Opiates and Alcohol. Important Clinical Connections</td>
<td>Albrecht Ulmer (Stuttgart, Germany, EU)</td>
</tr>
<tr>
<td>4:40</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>5:00</td>
<td>End of Forum</td>
<td></td>
</tr>
</tbody>
</table>

In collaboration with EUROPAD-Italia and Italian Society of Addiction Medicine (SITD)

WELCOME RECEPTION  Sunday, April 26, 2009  5:30 PM – 7:30 PM

The Welcome Reception affords all participants the opportunity to make new professional and personal acquaintances, as well as to enjoy some relaxing time with old friends and colleagues not seen for too long.
EXHIBIT AND POSTER SESSIONS

The National Conference serves as a central gathering point for the opioid treatment community and offers significant opportunities for exhibiting companies and attendees to interact with other professionals who are devoted to the treatment of opioid dependence throughout the nation and abroad. The registrants will consist of the decision makers in this field who spend over $1 billion annually treating more than 260,000 patients in opioid treatment programs.

In order to provide exhibitors with steady exposure to conference attendees, all continental breakfasts, refreshment breaks and poster sessions will be held exclusively in the exhibit area. An Exhibitor’s Networking Event will be held Monday, April 27th to encourage contact and dialogue between opioid treatment professionals and the exhibiting companies.

Exhibit Hours
Sunday, April 26 - 2:00 PM – 5:00 PM  Monday, April 27 - 7:30 AM – 4:30 PM  Tuesday, April 28 - 7:30 AM – 1:30 PM

Exhibitors as of December 29, 2008

AAOTD  Covidien - Mallinckrodt  STERLING Reference Laboratories
Ammon Analytical Laboratory, Inc  Emerging Solutions in Pain  Substance Abuse and Mental Health
ASI-MV Connect/Inflexxion, Inc.  Friends Medical Laboratory, Inc  Services Administration
ATP-NSM Insurance Group  National Institute on Drug Abuse (NIDA)
The Joint Commission
Bendiner & Schlesinger, Inc.  N vagyics
Tower Systems, Inc
C & C Containers, LLC  O.Berk Co. of New England & Kols Container
Treatment Software Solutions
CARF  OraSure Technologies, Inc
VistaPharm, Inc
Cebert Pharmaceuticals, Inc.  Redwood Toxicology Laboratory, Inc
Willow Laboratories & Medical Center
Clinical Science Laboratory, Inc.  San Diego Reference Laboratory
Community Collaborations and Partnerships: Improving Patient Care within Budget Realities
Council on Accreditation

Poster Topics Include: (International and domestic posters will provide valuable research findings to treatment providers.)

• For More Effective Treatment & Better Outcome
• Cultural Factors Impacting Compliance of African Americans in Opioid Treatment Programs
• Community Collaborations and Partnerships: Improving Patient Care within Budget Realities
• Reproductive Recovery: The Mommy Program - A Collaborative Relationship Between Choices Recovery Program Methadone Clinic and Luzerne County Children and Youth Parenting Center
• Posttraumatic Stress Disorder and Substance Use among Women in Methadone Maintenance Clinics: Screening, Staff Training and Treatment
• Accreditation Standards Improvement Initiative
• Recovery Focused Care: Medication Assisted Recovery is more than Just Medication
• Starting Treatment with Agonist Replacement Therapy: The START Study: The Community Treatment Provider’s Experience
• Rapid Growth, Rapid Change: Growing High Integrity Programs through Effective Management and Vision
• Beyond Medication: Integrating Psychotherapies in OTP
• HIV Prevention Interventions: Targeting the Problem of Engaging in Sex under the Influence of Drugs and Alcohol while in Substance Abuse Treatment
• The Anxious Patient: Treatment and Self-Treatment
• Comprehensive Methadone Treatment as HIV Prevention: Implementation and Scale-up of Methadone Treatment in Vietnam as a Government of Vietnam/PEPFAR Collaboration
• Medication Assisted Recovery and Support: A 12 Step Fellowship Program for the Medication Assisted Patient in Recovery
• OTP Treatment Experience Among Incarcerated Men in Puerto Rico
• Outcome Study of the Living Skills Recovery Curriculum with Opioid Dependent Mentally Ill Clients
• The Road Less Traveled: Client Utilization of a Methadone-to-Abstinence Residential (MTAR) Therapeutic Community Program in NY
• Patient Safety In Opioid Addiction Treatment - A Survey of OTP Training in Pennsylvania
• Boston’s OTP Journey from 1972-2009
• Mortality Report Form
• The New Strategies of Harm Reduction Project on Drug Prevention in Taiwan
• Survey Analyses for Implementing an Electronic Information System to Enhance Practice at an Opioid Treatment Program
• Katrina and Rita - Two Years Later
• One Stop Shop Model of Treatment and Care Model for Street Drug Users
• Gender Differences in Methadone Maintenance Treatment Outcomes
• Psychiatric and Substance use Correlates of Physical Pain in Methadone Maintenance Treatment
• HAART Use in an Integrated Suboxone/HIV Primary Care Program
• Smoking Cessation Program in a Methadone Maintenance Program
• Work Matters: The Importance of Integrating Vocational Rehabilitation Services to Improve Treatment Outcomes
• Buprenorphine Maintenance in Jail and at Post-Release
• Buprenorphine: A Guide for Nurses
• Early Implementation of Case Management in Medication Assisted Treatment
• Measuring Performance in Use of Medication Assisted Treatment with Buprenorphine
• Opioid Addiction Treatment Modalities in Ukraine. Availability and Challenges
• Former Heroin Addicts Currently in Methadone Maintenance Treatment (MMT) with Axis I & II Psychiatric Diagnosis Presented Best Cumulative Retention Compared to no Axis I and no Axis I&II Groups
• Observational Study and Follow-Up of Patients in Treatment with Olanzapine and Substitutive Drug

Posters are in place at all times when the exhibit hall is open – Authors will present their topic on Tuesday from 7:30 AM – 8:45 AM.

The Exhibit Networking Break is supported through a grant from O.Berk / Kols Containers and Tower Systems, Inc.

The Tuesday Continental Breakfast is supported through a grant from Reckitt-Benckiser Pharmaceuticals.

The Wednesday Continental Breakfast is supported through a grant from VistaPharm, Inc.
CONGRESS SESSIONS  
Monday, April 27, 2009

OPENING PLENARY SESSION
8:45 am – 10:15 am

Meeting Challenges In Turbulent Times: New York State’s Transformed Treatment System and Continuum of Care

• Welcome and Introductions
  Ira J. Marion, Conference Chairperson, AATOD 2009

• The State of the Field: Meeting Challenges in Turbulent Times
  Mark W. Parrino, President, American Association for the Treatment of Opioid Dependence, Inc.

• Transforming Methadone Treatment in New York State
  The Honorable Karen M. Carpenter-Palumbo, Commissioner, New York State Office of Alcoholism and Substance Abuse Services

• Keynote Address: New York State’s Commitment to Prevention, Treatment and Recovery
  The Honorable David A. Paterson, Governor, State of New York (Invited)

The Opening Plenary will focus on the significant challenges facing our field. Conference Chairperson, Mr. Ira J. Marion, will open the conference by welcoming attendees to New York City and will provide an overview of the conference. Mr. Mark Parrino, AATOD President, will present an overview of OTP issues and concerns and AATOD activities to meet these challenges now and into the future. Two exciting speakers follow; conferees will hear from New York State’s Commissioner of Alcoholism and Substance Abuse Services, Karen M. Carpenter-Palumbo, whose energy and commitment will motivate all in attendance. Early in her tenure as Commissioner, Ms. Carpenter-Palumbo saw the need for a plan to transform New York’s OTP system, reforming regulations, taking OTPs out of the “silo,” and making them full partners in the prevention, treatment and recovery continuum in New York State, the largest system in the nation. Commissioner Carpenter-Palumbo will outline New York’s transformation plan for OTPs. An additional honor will be a major address by Governor David A. Paterson as Keynote Speaker. Governor Paterson will speak about the importance of substance abuse treatment in human services, the work his administration has done to improve cooperation between all impacted state agencies and the partnership that has been forged with local service providers and the State of New York, strengthens the model of care New York provides for its most vulnerable citizens.

10:30 AM – 12:00 Noon

Workshop Sessions
Workshops will offer a chance to review the latest treatment data and health care policies, examine their implications for our patients, and strengthen the skills needed to improve the quality of services.

Basic Track: This year we will again be offering a special sequence of workshops designed to act as a refresher for seasoned professionals and to meet the needs of individuals who are new to this field. Those who attend all six sessions listed will receive a special certificate of completion. Basic Track Workshop Sessions: A1, B1, C1, D1, E1 and F1

A1 Medical Issues for Counselors: Four Patient Questions about Methadone
Judith Martin, MD, BAART Turk Street Clinic, San Francisco, CA

This workshop introduces the medical model of addiction, and reviews questions commonly asked by patients about the medication itself. Why is methadone better than using heroin? How do I know I’m taking the right dose? How long should I stay on methadone maintenance? What are the side effects of methadone? Counselors use this information in their therapeutic alliance with the patient who is enrolled in methadone maintenance.

* Note: Basic Track

A2 How to Effectively Communicate Research and Policy Recommendations to Key Decision-Makers
Jenny Collier, JD, Independent Advocacy and Policy Consultant, Washington, DC

Opioid-based treatment is one of the best-researched addiction treatments in the world, but policy makers continue to doubt its effectiveness. Such misunderstanding reduces funding for and stalls implementation of important opioid treatment policies. In this workshop, researchers, providers and advocates will improve their ability to translate opioid treatment research and practice into concrete policy recommendations. Participants will gain tools to effectively communicate these recommendations to local, state, and federal decision-makers.
A3  Staff Training and Program Implementation of an Evidence-Based Treatment for Co-Occurring PTSD in Community OTPs
Mark P. McGovern, PhD, Dartmouth Medical School, Lebanon, NH
Phil F. Richmond, MS, Hartford Dispensary, Hartford, CT
Aliza Castro, MSW, Hartford Dispensary, Hartford, CT

This workshop describes the development and implementation of a simple, practical evidence-based practice, cognitive behavioral therapy, for patients in methadone maintenance, for one of the most vexing co-occurring psychiatric disorders: Posttraumatic Stress Disorder (PTSD). There will be a description of the outcomes of this project along with lessons learned, challenges and recommendations for implementation in other settings. New data, from a randomized controlled trial comparing the CBT with individual addiction counseling, will also be presented.

A4  From Conception to Postpartum: Update of Methadone during the Perinatal Period
John McCarthy, MD, Bi-Valley Medical Clinic, Sacramento, CA
Hendree Jones, PhD, Johns Hopkins University, Baltimore, MD
Karol Kaltenbach, PhD, Thomas Jefferson University, Philadelphia, PA

This workshop focuses on three issues. The first presentation reports on outcomes of neonates born to women who conceived and are maintained on methadone throughout pregnancy; the second reviews data supporting the current USA clinical guidelines regarding medication assisted withdrawal during pregnancy; and the third presents the results of a retrospective study tracking maternal dose at the beginning of the third trimester, changes across the third trimester, dose at delivery, and dose changes throughout six (6) weeks postpartum.

A5  Philadelphia Prison Experiment: 10 Years of MAT within A Correctional Setting on A Limited Budget
John T Carroll, NCAC II / CCS, Northeast Treatment Centers, Philadelphia, PA
Roland Lamb, MA, Philadelphia Department of Behavioral Health, Philadelphia, PA

Over the past 10 years, an evolutionary collaboration has developed for the management of methadone maintained inmates incarcerated within the Philadelphia Prison System. The treatment model evolved from short term methadone detoxification into a state-of-the-art treatment program providing methadone maintenance to 400+ inmates a year with innovative re-entry services yielding extraordinary outcomes. The program design successfully incorporates the culture, factors and forces of a correctional environment to deliver comprehensive cost effective MAT.

1:30 PM – 3:00 PM
Hot Topic Round Tables

Hot Topic Round Tables are facilitated discussions that focus on current controversial issues in an informal context. Meet with your colleagues as you learn, challenge, support and share your views with others who may have similar or different opinions, experiences, or interests. Engage in one or more of these facilitated discussions.

Experienced leaders in the field will be facilitating these sessions:
• Discharges for financial reasons
• Smoking Cessation in MAT
• Disaster Planning in OTPs
• OD prevention in OTPs
• Aging issues
• Driving safety

The Policymaker’s Luncheon on Monday, April 27, 2009 is supported through a grant from Bendiner & Schlesinger, Inc.
CONFERENCE SESSIONS  Monday, April 27, 2009

1:30 PM - 3:00 PM

#1 Integrating Routine Domestic Violence Assessment and Intervention into Opioid Dependency Settings
Monica Joseph, PhD, Addiction Research and Treatment Corporation, New York, NY
Michelle Melendez, MSW, Metropolitan Center for Mental Health, New York, NY
Melissa Mei-Yu Lin Chu, MS, Addiction and Research Treatment Corporation, New York, NY

This presentation will address the research findings related to the prevalence of substance abuse and domestic violence, as well as attitudes and perceptions of staff in opioid dependency programs and domestic violence settings. A current model for assessing domestic violence within substance abuse settings and substance abuse within domestic violence settings will be described. Concrete strategies for addressing the knowledge, attitudes/values and skills needed for corresponding interventions will be presented. Variables that should be integrated into developing a seamless resource network will also be examined.

#2 Electronic Health Records and Opioid Treatment Programs
Nicholas P. Reuter, MPH, Substance Abuse and Mental Health Services Administration, CSAT, Rockville, MD
Mary Murphy, Veterans Affairs Hospital OTP, Washington, DC
David Picolli, Discovery House, Providence, RI

The use of electronic health recordkeeping will continue to expand in the coming years. This workshop will highlight two OTP systems that have complete electronic health records (EHR). A CSAT representative will discuss how EHRs align with Federal recordkeeping requirements. Participants will understand the challenges of establishing a system, together with the reimbursement and other advantages tied to EHRs.

#3 Methadone Maintenance and the Child Welfare System: What We Know and What We are Learning
Steve Hornberger, MSW, National Association for Children of Alcoholics, Silver Spring, MD
Patti Juliana, MSW, Beth Israel Medical Center, New York, NY
Naomi Weinstein, MPH, Center on Addiction and the Family, Phoenix House, New York, NY

This session will address developing collaborative relationships between the child welfare system and methadone programs, improving outcomes for families and increasing family involvement as a combined effort. Presenters will discuss a cross system training initiative in New York City, resources to help patients and family members and share one agency’s change process to partner with the child welfare system.

4:00 PM – 5:30 PM

Workshop Sessions

B1 Alcohol Abuse in Methadone Maintenance Patients: Understanding and Addressing a Serious Problem
Allan J. Cohen, MA, Bay Area Addiction, Research and Treatment (BAART), Sherman Oaks, CA
Adeline Nyamathi, PhD, UCLA School of Nursing, Los Angeles, CA
Judith Martin, MD, BAART Turk Street Clinic, San Francisco, CA

This workshop presents the problem of alcohol abuse in agonist-maintained patients including a review of prevalence rates across populations with differing demographics as well as evidence-based outcome of treatment interventions. We will explore a variety of alcohol-related clinical issues faced by treatment providers and discuss how these issues are addressed in the OTP setting. A description of findings from an NIAAA-funded research study using motivational interviewing will be presented.

* Note: Basic Track
**B2** Peer-to-Peer Recovery Services in MAT: Early Lessons from the MARS Project  
Joycelyn S. Woods, MA, National Alliance of Methadone Advocates (NAMA), New York, NY  
Jo L. Sotheran, PhD, National Alliance of Methadone Advocates (NAMA), Brooklyn, NY  
Howard S. Lotsof, BFA, National Alliance of Methadone Advocates, Dora Weiner Foundation, Staten Island, NY  

Peer-to-peer recovery support services are in their infancy in MAT, although well established in other treatment modalities. The National Alliance of Methadone Advocates was awarded the first MAT project within CSAT's Recovery Community Services Project. The Medication Assisted Recovery Services (MARS) project, with its central vision of a completely peer-based project, is now in its second year. This presentation will describe three aspects of the program, and how they have evolved since the program began, with particular attention to the effects of being embedded in MAT.

**B3** Expansion of Buprenorphine Treatment for Opioid Dependence into Community Settings: A State-Funded Best Practice Model  
Colleen LaBelle, RN, Boston University Medical Center, Boston, MA  
Hilary Jacobs, MSW, Bureau of Substance Abuse Services, MA Department of Public Health, Boston, MA  

This workshop will highlight a best practice model that allowed for the expansion of buprenorphine treatment in Massachusetts providing training, technical support, and nurse care managers to 20 community sites with State funding. The model addressed barriers to treatment by providing clinical and technical support to physician providers in community settings. This innovative demonstration project has allowed for the expansion of opioid treatment into primary care practice setting while requiring integration with behavioral health care.

**B4** Consideration of Cognitive Disabilities in the Treatment of Opioid Dependence  
Frank R. Sparadeo, PhD, Informed Interventions, LLC, East Greenwich, RI  

Cognitive impairments can occur directly from substance abuse or from other causes such as developmental disability or traumatic brain injury. This workshop has been developed to introduce substance abuse counselors to the process of identifying and treating individuals with co-occurring cognitive disability and substance abuse. This workshop will review normal brain-behavior relationships, the impact of substance abuse on cognitive functioning, how to assess cognitive functioning, and treatment modifications for various types of cognitive impairments.

**B5** Increasing Treatment Retention to Improve Outcomes: Patients’ Perspectives  
Robert P. Schwartz, MD, Friends Research Institute, Baltimore, MD  
Shannon G. Mitchell, PhD, Friends Research Institute, Baltimore, MD  
Sharon Kelly, PhD, Friends Research Institute, Baltimore, MD  

Through NIDA support, Friends Research Institute and its OTP partners are examining ways to prevent premature discharge. Insights from in-depth interviews of patients discharged from six OTPs; findings from a study of interim methadone treatment as an approach to enhance early treatment retention; and, data from a study of patient satisfaction will be presented. Specific recommendations will be made to increase patient retention through the use of patient perspectives.

6:00 pm - 8:00 pm  
**TOWN HALL: A Continuing Community Discussion of How OTPs and the Treatment Community Can Work Together to Prepare for the Next “Service Discontinuity”**  
Arlene Stanton, PhD, Division for Pharmacologic Therapies (DPT), Center for Substance Abuse Treatment (CSAT) Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD  

In the aftermath of 9-11, SAMHSA’s D-ATM project (“Digital Access to Medication”) was conceived as a technological approach to help ensure that OTPs could effectively and safely provide medication to patients who had been displaced from programs where they were normally enrolled. In 2002, SAMHSA/CSAT, working with COMPA and a Steering Committee representing a range of stakeholders, conducted a feasibility and planning study, followed by a smaller developmental study. This confirmed the need for a deliberately simple, web-based, centralized database containing only the information needed by an OTP to verify patients’ identity and to provide accurate and safe dosing. In 2005, SAMHSA provided funding to develop the infrastructure for and conduct a limited pilot-test of the system (now known as D-ATM) in 3-4 major metropolitan areas. The purpose of Phase III, recently launched, will be to pursue a national expansion of the system, which promises to provide an important tool for OTPs and a critical means to assure service continuity to patients in treatment for opioid dependence. (More background can be found at the D-ATM website, http://datm.samhsa.gov/.)
However, the events of 9-11, Katrina, and many large-and smaller-scale disasters that have followed since the last AATOD conference, have made OTP staff, administrators, and patients all too aware of the kinds of policy issues that can emerge in the wake of disaster, beyond the scope of D-ATM to address.

This Town Hall will begin with a brief overview and status report on D-ATM as Phase III commences, moving to an open discussion of the kinds of disaster preparedness issues that have been encountered in dealing with real-life situations, whether widespread disasters or more routine service disruptions. For instance, how have programs dealt with reimbursement issues or differences in dosing practices, when faced with unfamiliar patients from other programs? These are complicated issues and it is hoped this Town Hall will provide one means to continue a dialogue among the many members of the treatment community toward identifying which issues still need attention and who best can address them. Representatives of CSAT and other federal and state agencies, members of the D-ATM Steering Committee, and program directors, patients and staff who have had experience in working with DATM or in dealing with disaster first-hand, are especially encouraged to attend.

Sponsored by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment (SAMHSA/CSAT).

MIDDLE PLENARY SESSION

Tuesday, April 28, 2009

8:45 AM - 10:15 AM

Integrating Recovery-Oriented Systems of Care Into Medication Assisted Treatment: People and Outcomes

Two Personal Stories of Recovery through Medication Assisted Treatment
Anthony Badger, Union, NJ
Carolyn Visconte, Schenectady, NY

Medication Assisted Treatment is Recovery
William L. White, MA, Senior Research Consultant, Chestnut Health Systems, Bloomington, IL

Integrating Recovery Oriented Systems of Care into Medication Assisted Treatment
H. Westley Clark, MD, JD, MPH, CAS, FASAM, Director, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD

The theme of the Conference “Treatment and Recovery – People and Outcomes” is an effort to urge OTPs to renew their focus on the patients in their treatment programs in new and more significant ways. Individualized treatment and a renewed focus on outcomes are critical for a recovery plan for each patient. Treatment is always about the people whose lives are changed in different ways and the way they integrate their recovery into the fabric of community life. The integration of MAT and ROSC provides the opportunity to all treatment and recovery providers to identify best practices and desired outcomes to enhance the quality of life for each patient. Renowned recovery pioneer, William L. White, will speak about the growth of the recovery movement this decade and how it has embraced medication-assisted treatment as part of the recovery community. Dr. H. Westley Clark will present the importance of recovery-oriented systems of care in the SAMHSA matrix and will discuss the important new CSAT publication, ROSC in MAT. Most significantly, two patients in long-term recovery through participation in medication-assisted treatment will put a face and voice to their recovery with their compelling and important stories.

10:30 AM – 12:00 NOON

Workshop Sessions

C1 A Guide to Implement a More Recovery Oriented System of Care in Opiate Treatment Programs

Walter Ginter, Medication Assisted Recovery Support (MARS) Project; National Alliance of Methadone Advocates (NAMA), New York, NY
Lisa Mojer-Torres, JD, Faces and Voices of Recovery (FaVoR), Washington, DC
Shannon B. Tait, MPA, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD

In May 2008 CSAT convened a panel to create, “A Guide to Introduce and Implement a More Recovery Oriented System of Care in Opiate Treatment Programs”. CSAT’s charge to the panel stated that in this system, treatment is no more or less important than any other support. This workshop will introduce and explain what a recovery oriented system is, point out problems unique to OTP’s in implementing such a system, and suggest possible solutions.

*Note: Basic Track
C2 Buprenorphine in the OTP: A Full Spectrum of Options
Heidi Shah, MD, Spectrum Health Systems, Westborough, MA
Kristin Nolan, MA, Spectrum Health Systems, Worcester, MA
This workshop will describe four different buprenorphine treatment plans currently being offered by Spectrum Health Systems through several OTP’s in Massachusetts. These plans include: 1) outpatient detoxification, 2) induction phase observed treatment with transfer to a community provider for maintenance, 3) observed daily dosing while awaiting transfer to a community provider for maintenance, and 4) maintenance treatment by prescription using a chronic disease model of care.

C3 Treatment of Opioid Dependence and ADHD/ADD with Methadone or Buprenorphine and Central Stimulants
Olof Blix, MD, County Hospital Ryhov, Jonkoping, Sweden
Peter Nilsson, County Hospital Ryhov, Jonkoping, Sweden
ADHD and ADD together with drug dependence is common. Data at our clinic indicate that 29% of MAT patients also have symptoms of adult ADD or ADHD. Most identified patients report improvements in every day functioning when a central stimulant is added to their daily methadone or high dose buprenorphine medication. Focus will be on diagnostic methods, evaluation, a formalized follow-up protocol, and the every day challenges in working with this long over-looked patient population.

C4 What to do about QT: Assessing and Reducing Cardiac Risk in the OTP
Judith Martin, MD, BAART Turk Street Clinic, San Francisco, CA
Mori J. Krantz, MD, University of Colorado, Denver, CO
Barry Stimmel, MD, Mt. Sinai School of Medicine, New York, NY
Methadone is one of many medications that can cause torsades, a rare cardiac arrhythmia. One in five maintenance patients might be at risk, and two percent are at high risk of this serious cardiac complication. This workshop presents the draft of the findings. Solicitation of comments from the audience will be part of CSAT’s Fields Review process.

C5 Outcomes Research: Getting Results that Mean Something
Erin Stevenson, MSW, University of Kentucky CDAR, Lexington, KY
Hilary Jacobs, MSW, MA, Department of Public Health Bureau of Substance Abuse Services, Boston, MA
Frederick Pottle, MPA, CRC Health Group Recovery Division, Carlsbad, CA
This panel offers different perspectives on outcomes data collection and dissemination for opioid replacement treatment populations. Kentucky’s Opiate Replacement Treatment Outcome Study, Massachusetts’ Methadone Treatment Quality Assurance System, and CRC Health Group’s outpatient clinic network will help answer: How to cost-effectively collect patient level data and get results? How to respond to NOMS and other State, local and Federal data requests? How to translate outcomes into usable products for clinicians, treatment centers and policy-makers?
CONFERENCE SESSIONS  Tuesday, April 28, 2009

1:30 PM – 3:00 PM  Workshop Sessions

D1 Integrating Treatment for Co-Occurring Disorders
Joan E. Zweben, PhD, East Bay Community Recovery Project; Oakland, CA; University of California, San Francisco, CA

This workshop will discuss how counselors can help integrate the treatment of psychiatric disorders into the opioid treatment program. We will discuss addictive behavior and coexisting psychiatric problems, barriers to addressing them, how to educate the patients appropriately, how to prioritize treatment tasks, and how to work with physicians around psychotropic medication.

*Note Basic Track

D2 Developing & Integrating Peer Mentoring Services
Robert C. Lambert, MA, Connecticut Counseling Centers, Inc., Norwalk, CT
Kurt Kemmling, CT Chapter National Alliance Methadone Advocates; CT Chapter National Alliance Methadone Advocates, Norwalk, CT

This workshop will focus on the development, implementation, and integration of peer mentoring services within a methadone treatment program. Potential benefits relating to patient outcomes and staff utilization management will be discussed. The presenters will focus on providing information the workshop participants will need to replicate all or part of the initiative at their own programs. One key area of focus will be the development and implementation of a training curriculum for the peer mentors.

D3 Genetics and Addiction: A Current and Future Perspective
Mary Jeanne Kreek, MD, The Rockefeller University Hospital, New York, NY
Allan J. Cohen, MA, Bay Area Addiction, Research and Treatment, San Francisco, CA
Louise Haynes, MSW, Medical University of South Carolina, Columbia, SC

Epidemiologic research has shown that the relative risk of developing an addiction to a substance, following self-exposure, ranges from 30 – 60 percent. Over the past decade significant advances in molecular genetics have identified a variety of variants of specific genes some of which are directly related to processes known to be involved in addiction while others, which are less well understood, offer future discovery. Staff and patients of community opioid treatment programs can and will be involved in the future development of genetic research, this will lead to a better understanding of addiction and thus to more specific treatment approaches which will produce improved treatment outcomes. This session will describe some of the current and future genetics research on opioid addiction and its implications for the treatment community.

D4 Evaluating Multiple Buprenorphine Treatment Approaches and Integration into an IOP
Robert M. Freeman, BS, The APT Foundation, New Haven, CT
Lynn M. Madden, MPA, The APT Foundation, New Haven, CT
Sam A. Ball, PhD, The APT Foundation; Yale University School of Medicine, New Haven, CT

The APT Foundation, located in New Haven, CT maintains an integrated system of Buprenorphine treatment and maintenance services by offering three distinct levels of care including Physician-based practice; Physician-based practice in a traditional outpatient setting; and Buprenorphine Maintenance integrated into an OTP. Our evaluation of each program consists of data obtained from the self-administered Basis-24; baseline admission data; patient retention; service level data; and finally patient urinalysis data. Through analysis of patient response in each setting, a system of matching patients to service level as well as the development of a Buprenorphine continuum of care will be discussed.

D5 Removing Systems Barriers to Implement Evidence-Based Practices
Todd Molfenter, PhD, NIATx- University of Wisconsin Madison, Madison, WI
Victor Capoccia, PhD, NIATx and Open Society, Madison, WI
Thomas McLellan, PhD, Treatment Research Institute, Philadelphia, PA

In 2006 the Robert Wood Johnson Foundation initiated the Advancing Recovery program intended to promote adoption of five evidence-based practices in the addiction treatment (wrap around services, continuing care, medication assisted treatment, screening and brief intervention, and psychosocial interventions). This workshop will describe that program, present case examples from four states of how the system changes implementation and what effect they had. A discussion of the program’s implications for implementing evidence-based practices will also be included.
Introduction to the Awards Program

Please join us for the centerpiece of our Conference, a moving tribute to those individuals who have been nominated and selected by their peers for extraordinary service in the opioid treatment community. These successful Award recipients have devoted themselves to improving the lives of patients in our treatment system. Dr. Vincent Dole and Dr. Marie Nyswander were the first recipients of this Award in 1983. The Association has been responsible for bestowing this honor since the first Regional Conference of 1984 in New York.

The 2009 American Association for the Treatment of Opioid Dependence National Conference recognizes outstanding contributions to opioid treatment by honoring the following individuals with the Nyswander/Dole Award.

Robert K. Brooner, PhD  Maryland
Dr. Brooner has tirelessly and successfully served the medication-assisted treatment community in Maryland and elsewhere for more than 20 years. Some of the work that captured the committee’s enthusiasm includes: 1) the creation of an adaptive treatment approach for opioid dependence that rapidly adjusts the scope and intensity of services to sustain good clinical response from patients. The Joint Commission honored this work by naming him a 2007 winner of the Ernest Amory Codman Award for innovative treatments that improve quality-of-care and patient safety, and identified the treatment as a “gold standard” for medication assisted programs in the 21st century; 2) his development of a citywide treatment initiative that makes specialized services readily available to poor treatment responders in publicly-supported treatment programs in Baltimore that use methadone; and 3) despite considerable demands on his time, Robert continues to provide clinical care to patients and makes himself readily available as an advisor and mentor to many people and programs.

Peter Coleman, MS  New York
Throughout his career, Peter has been an advocate for moving the opioid treatment system in New York State towards a more patient-centered, evidenced-based approach. Peter has advocated for the provision of comprehensive and co-located services consistent with the chronic disease model of care. In the best traditions of Marie Nyswander and Vincent Dole, Peter believes in listening to patients and insists that out treatment approach must always be respectful of patients’ rights, human dignity, and self-determination. Peter has worked towards these goals in his former position at Staten Island University Hospital as well as in the many opioid treatment clinics operated by the New York City Health and Hospitals Corporation. Peter is a leader in our field in New York. He generously shares his time, expertise, and wisdom with others through his work on the COMPA Board and the New York State Governor’s Advisory Committee for Alcoholism and Substance Abuse Treatment. Most recently Peter has been an active member of the OASAS Methadone Transformation Advisory Workgroup (MTAG) which seeks to mainstream medication assisted treatment throughout the large addiction treatment system in New York. Peter’s principled yet practical voice has been a major force in helping to develop a better OTP treatment system in our state.

Kim Comstock, MEd  Texas
Kim Comstock M.Ed., LPC, an NTP sponsor since 1997, focuses primarily on community education, patient advocacy and empowerment, harm reduction and progressive program implementation. Her efforts include teaching methadone awareness (St. Edwards University and Institute for Chemical Dependency Studies), co-founding Texas Opioid Treatment Alliance, authoring articles advocating MAT for Recovery Today Newspaper, facilitating Texas CPS policy changes to support OTP patients and creating the first PAG (patient advocacy group) in Texas. Kim’s programs train interns from local schools and universities. She donates thousands of dollars per year to the clinic’s PAG to help patients with fees/financial hardships. She welcomes needle exchange to operate at the clinics. Her programs offer free acupuncture, yoga, a space for MA groups and financial incentives encouraging patients and their families to participate in services. Kim has always placed the interests of her patients as primary in all of her work.

Mercedes Lovrecic, MD  Slovenia
Mercedes Lovrecic MD, MSc – Slovenia (EU) has been a lecturer and practicing clinician in a methadone clinic in Slovenia since 1996. In 2002, with the support of European colleagues she co-founded the first outpatient clinic in Izola, Slovenia for the treatment of addiction and psychiatric comorbidity. In 2002, she received the “Chimera Award” in Oslo for her contribution to the development of effective opioid treatment in Europe. She also works at the National Institute of Public Health for the Republic of Slovenia and has served as a member of the Steering Group for the European Union Action Plan on Drugs. Mercedes is widely published and has frequently presented at EUROPAD and AATOD conferences.

Judith Martin, MD  California
In her 22 years in the addiction treatment field, Dr. Martin has assumed significant leadership roles in providing top quality treatment in a supportive and respectful manner. She is active as a physician working with patients, a teacher, a member of numerous expert committees, chair of important committees, and currently, President of the California Society of Addiction Medicine. Dr. Martin is appreciated for her warmth, intelligence, and graceful leadership style. She is highly knowledgeable, and able to communicate with a wide range of people in a manner that promotes finding common ground. Beginning counselors are enthusiastic about her ability to talk from their perspective, putting medical issues in understandable form. Advanced professionals appreciate her knowledge of the research literature and ability to describe complex issues succinctly. These qualities are evident in her work on many expert work groups, her participation in research, and her publications.

Gloria J. Mouzon, MD  Illinois
Through her work as a practitioner at several facilities and on statewide committees over the past 25 years, Dr. Mouzon has made meaningful and consistent contributions that have had significant impact on opioid treatment in Illinois. Due to the high quality of her work and her commitment to patients, Dr. Mouzon has earned the respect of the State Methadone Authority and colleagues throughout Illinois. Patients, regulating authorities, and program staff all rank Dr. Mouzon as an outstanding physician. Dr. Mouzon is highly skilled, demonstrating sound clinical judgment in working with patients with diverse needs. Her warm and open style helps to foster teamwork between nurses, counselors and patients. Dr. Mouzon has an amazing spirit. She approaches her work with honesty and integrity, and holds a deep respect for patients and their right to self-determination. As a physician, Dr. Mouzon has raised the bar for patient care.
Dr. Pomm has worked in addiction treatment over 20 years and holds medical licenses in both Florida and Virginia. He is the Medical Director for River Region Human Services in Jacksonville, Florida. He is also the Medical Director for the Professionals Resource Network/Impaired Practitioners Program of Florida. He developed the first dual diagnosis program for methadone patients with serious psychiatric disorders in 1994 and has continued to set the standard for dual diagnosis care for this population. Dr. Pomm has also worked tirelessly with Family Practice physicians to enhance their understanding and treatment of substance use disorders, but particularly to the issues related to opiate addiction. He has championed the needs of impaired healthcare professionals in order to support their recovery and return to the workforce, including professionals on methadone and/or Suboxone. Dr. Pomm represents opiate addiction treatment services on several committees and workgroups at the state level.

Deborah Powers, BS Wisconsin

Ms. Powers is a tireless State Methadone Authority. Frequently she is at the office on weekends and available on her scheduled days off to resolve patient care issues. She is always willing to share her knowledge of pharmacology during patient staffings, especially drug interactions for pregnant women and the fetal impact. She has even provided clinical consultation to the Chief Medical Officers within the Department on the issue of drug interactions. Medication-assisted treatment remains one of the most stigmatized modalities in the treatment for substance use disorders and controversy surrounds it to this day. Deb has done a tremendous job to reduce the stigma and increase awareness around methadone maintenance. She has reminded all of us that treatment professionals remain leaders in the field of stigma reduction by conveying the understanding of the neuroscience of addiction, treatment effectiveness, and to act in best interest of our patients for timely coordination of care.

Alan Wartenberg, MD Rhode Island

Dr. Wartenberg is the former Medical Director of the Addiction Recovery Program at Faulkner Hospital, and recently retired as the Corporate Medical Director of Discovery House Programs. He is the Associate Medical Director for the Providence VA Opioid Treatment Program and on the faculty of Tufts University School of Medicine. He is a fellow of the American Society of Addiction Medicine and the American College of Physicians specializing in medical management of addiction problems, including detoxification, and addiction psychopharmacology focusing on opioid treatment, including methadone and buprenorphine. He is a respected author and teacher in these areas. He has advocated for patients in need of treatment to have easy access and is passionate about providing excellent care to his patients.

Dr. McLellan is perhaps best known for his pioneering introduction of the Addiction Severity Index and Treatment Services Review in the 1980s. Dr. McLellan later conceptualized data-driven measurement of treatment effectiveness, performance, data-based monitoring, and performance-based monitoring and refined substance abuse treatment system. Through his research and extensive knowledge of substance abuse treatment systems, Dr. McLellan has become a persuasive proponent of the view that addiction is a chronically relapsing condition, one that must be continually monitored and managed. Dr. McLellan has published more than 400 articles and chapters on addiction research and serves as Editor-in-Chief of the Journal of Substance Abuse Treatment. He is also an advisor to numerous government and nonprofit scientific organizations, including the Office of National Drug Control Policy, Research and Evaluation; the National Practice Laboratory of the American Psychiatric Association, the Swiss National Science Foundation, the World Health Organization, and the Greek government.

Richard Lane / Robert Holden Patient Advocacy Award

Richard Lane was a long-term heroin user who, upon release from prison in 1967, was instrumental in establishing one of the Nation’s first methadone treatment programs. In 1974, he became the Executive Director of Man Alive and later served as Vice President of the American Methadone Treatment Association and as Vice Chairman of the Governor’s Council on Alcohol and Drug Abuse in Maryland. Mr. Lane then became advocate for methadone treatment and, by disclosing his own treatment experiences, provided inspiration to patients and colleagues alike. Robert Holden was also a recovering heroin user, who later became the Director of PIDARC, an outpatient methadone treatment program in the District of Columbia. He later served as the Vice President of the American Association for the Treatment of Opioid Dependence, succeeding Richard Lane’s term of office. This award was established in 1995 and recognizes extraordinary achievements in patient advocacy.

Walter Ginter, CMA

Mr. Ginter is the Project Director of NAMA’s Medication Assisted Recovery Service (M.A.R.S.) Project. He currently serves as national recovery advocacy and an At Large Director of Faces and Voices of Recovery (FaVoR), as a National Recovery Month Planning Partner, Chair of the Expert Panel creating a Guide to Implement a Recovery Oriented System of Care in OTP’s, and on the steering committee of the Digital Access to Medication (DATM) emergency database project. In NYS, he serves on the Methadone Transformation Advisory Group (MTAG) as Chair of the Recovery Committee and on the Commissioners Recovery Implementation Team (RIT). Walter has represented patients on more than 30 state and federal committees and panels and is responsible for creating NAMA’s Certified Methadone Advocate Training program. He is an extraordinary advocate who has raised awareness among patients, treatment providers and regulatory authorities. He has had a profound and positive effect on improving patient advocacy throughout the nation.
CONFERENCE SESSIONS  Wednesday, April 29, 2009

8:00 AM – 9:30 AM

Workshop Sessions

E1 Focus on the Therapeutic Relationship
Robert C. Lambert, MA, Connecticut Counseling Centers, Inc., Norwalk, CT

Research indicates that the quality of the therapeutic relationship has a greater effect on patient retention and outcomes than the specific counseling approach used. This “basic track” workshop will focus on the essential fundamental counseling skill of forming and maintaining the therapeutic relationship. The presenter will help the participants assess their current core counseling skill set and provide an overview of the counseling techniques used to form and maintain the therapeutic relationship.

*Note Basic Track

E2 Methadone and Social Responsibility: A Public Education Campaign
Ivette A. Torres, MEd, MS DHHS/SAMHSA/CSAT, Rockville, MD
Michele L Monroe, BS, DHHS/SAMHSA/CSAT, Rockville, MD
Ellen Frank, DHHS/SAMHSA/CSAT, Silver Spring, MD

The goal of this workshop is to educate participants on the available materials and goals of SAMHSA/CSAT’s public education campaign, which aims to inform consumers that methadone is an effective treatment for opioid addiction and pain management, when taken as directed, and to health care professionals and clinics that methadone is known to have a complex pharmacology with life threatening interactions when taken with other medications or not as prescribed.

Sponsored by the Center for Substance Abuse Treatment.

E3 Housing the Homeless Methadone Patient
Herman Joseph, PhD, Retired Research Scientist, New York, NY
Sam Tsemberis, PhD, Pathways to Housing, New York, NY
William Panepinto, MSW, NYS Office of Alcohol & Substance Abuse Services, Albany, NY

Many homeless methadone patients have a range of co-occurring mental disorders and histories of arrests and incarceration. They face a unique stigma which limits their acceptance into programs and services. Pathways to Housing has targeted a housing-first program for this group and the majority of patients have responded positively to services offered. NYS OASAS, cognizant of the issues facing service provision for homeless methadone patients, has developed plans to address this issue during this workshop.

E4 Methadone Mortality Update
Jane C. Maxwell, PhD, University of Texas at Austin, Austin, TX
Bruce Goldberger, PhD, University of Florida College of Medicine, Gainesville, FL
Robert Lubran, MA, Center for Substance Abuse Treatment; Substance Abuse and Mental Health Services Administration, Rockville, MD

This session will review current data on methadone-associated deaths and the extent such deaths might be related to clinical practices of programs to which, as well as strategies to improve the quality of reporting, including uniform nomenclature, case definitions, and standards for toxicological testing to encourage uniform reporting. It will also discuss the latest actions by authorities to address the problem through improved data collection and training health care professionals in the management of pain and addiction.

E5 The Matrix Model for Medication-Assisted Treatment
Michael J. McCann, MA, Matrix Institute on Addictions, Los Angeles, CA
Daniel George, MPH; Matrix Institute on Addictions, Los Angeles, CA

The Matrix Model Intensive Outpatient Treatment has been widely disseminated nationally and internationally. A growing number of providers of medication-assisted treatment have requested similar training and, in order to accommodate this need, the Matrix Institute has developed the Matrix Model Outpatient Program for Medication-assisted Treatment. This workshop will describe the core elements of the Matrix Model, address the special issues relevant to this patient population, and describe the program for medication-assisted treatment.

9:45 AM – 11:15 AM

Workshop Sessions

F1 One Year Later: Lessons Learned in the Implementation of Maryland’s Four Jail-based OTPs
Greg Warren, MA, MBA, Maryland Department of Public Safety and Correctional Services, Baltimore, MD
Akin Ayeni, MD, Correctional Medical Services, Inc., Baltimore, MD

The workshop will describe the challenges of implementing an OTP within a large and busy city jail, as well as how to forge linkages between institutional and clinical staff and with community OTPs. One year outcome data will be shared and its lessons learned- implications on clinical processes as well as its effect on the public health treatment system in Baltimore City.

* Note: Basic Track
F2 Expanding and Improving the Health Responses to Drug and Alcohol Addiction: The National Advocacy Campaign
Paul Samuels, JD, Legal Action Center, New York, NY
Gabrielle de la Gueronnier, JD, Legal Action Center, Washington, DC
This workshop session will focus on an upcoming national campaign to expand and improve the health responses to drug and alcohol addiction, and to eliminate discrimination against people in recovery. This session will highlight the campaign's focus on expanding access to medication-assisted treatment and eliminating policies that discriminate against people with opioid addiction histories. The presentation will include discussion of messaging and outreach strategies, and an update on federal and state policy matters.

F3 “Leave No Man Behind:” Clinical Considerations for Working with Veterans in Addictions Treatment
Carol Davidson, LCSW, Samaritan Village Veterans Program, New York, NY
Military service is a significant and transformative life experience that influences personal development throughout the life span of our veterans. This workshop will describe essential elements of the clinical culture, core treatment principles, and specialized services for combat-related PTSD that are offered in an addictions treatment program for veterans.

F4 Methadone Dose Reductions in Response to Benzodiazepine Abuse/Dependence: An Evaluation of a New Clinic Protocol
Janet G. Morgan, RN, Addiction Research and Treatment Services, Denver, CO
Denise E. Vincioni, MA, Addiction Research and Treatment Services, Aurora, CO
This presentation will examine the impact of a protocol of reducing methadone dose levels for patients testing positive for unapproved benzodiazepine use or for overt benzodiazepine impairment. Data will be presented on illicit opiate use, retention, and increase in other drug or alcohol use, as well as accidental multi-drug overdoses before and after implementation of policy; the benefits of the policy for safety, against the possible decrease in the efficacy of MAT will be discussed.

F5 Methadone Transformation in New York State – Process and Outcomes
Frank McCorry, PhD, NYS Office of Alcohol & Substance Abuse Services, New York, NY
Henry Bartlett, Committee of Methadone Program Administrators of New York State (COMPA), New York, NY
Belinda Greenfield, MA, NYS Office of Alcohol & Substance Abuse Services, New York, NY
New York State stakeholders, including opioid treatment providers, coalition and advocacy groups, in conjunction with the state chemical dependency agency, have begun a journey towards transforming the state’s opioid treatment system. The concepts that are driving transformation, the linkages with other inter/intra-agency workgroups, and fiscal reform efforts impacting these efforts will be discussed. The products and implementation strategies of methadone transformation will be presented from the state, provider and patient perspective.

CLOSING PLEINARY SESSION
11:30 AM – 12:45 PM
Policy, Programs and People
Robert B. Millman, Saul P. Steinberg Distinguished Professor of Psychiatry and Public Health, Weill Medical College, Cornell University and Director of the Drug and Alcohol Abuse Treatment and Research Service at the New York Hospital/Columbia Presbyterian Medical Center;
Mathea Falco, Esq., President of Drug Strategies, a non-profit research institute in Washington, D.C. promoting more effective approaches to the nation’s drug problems and former Assistant Secretary of State for International Narcotics Matters during the Carter Administration;

Our Special Closing Plenary will unite the voices and themes of AATOD 2009. Participants will gain an unique understanding of public policy and system change, treatment programs into the future and the importance of our patients and their needs. Mathea Falco, Robert Millman and Nick Miroff will bring new perspectives, insights and voices that shape change to our conference. Chaired by Dr. Millman, our speakers will provide focus and direction to our public policy agenda, our programs and the treatment we provide, culminating with a fascinating and powerful story told by an award winning journalist about a rural Virginia coal miner. As we return to our homes and workplaces, this closing plenary will emphasize our core mission, our patients and those who still need our help.
**TRAVEL INFORMATION**

World Travel, Inc. has been designated the Official Travel Coordinator for the 2009 American Association for the Treatment of Opioid Dependence, Inc. National Conference. We recommend that you contact World Travel Group Department at 800-341-2014 x3799 (Monday–Friday, 8:00 AM–5:30 PM EST) for your transportation. Please identify yourself as American Association for the Treatment of Opioid Dependence, Inc. or AATOD National Conference Attendee. World Travel will make all reservations based on the lowest fare available on date of issue.

*Please be advised that a service fee will be charged for each airline ticket purchased through World Travel. The service fee will appear as a separate charge on your credit card statement.*

**GROUND TRANSPORTATION**

FROM JFK AIRPORT

- Taxi $45 flat fee (plus tolls and gratuity).
- AirTrain $5 to NYC Subway, then a $2 subway fare on the A Train which stops 2 blocks from the hotel.
- Airlink $20 one way fare, Shuttle bus from airport to Manhattan hotels (go to ground transportation desk in airport and see staff or use courtesy phone) 877-599-8200.
- New York Airport Service $17–23 one way, Look for bus stop sign that says New York Airport Service (buses run every 20–30 minutes). Take bus to Grand Central Station and transfer for drop off at hotel 718-875-8200.
- SuperShuttle $15–20 one way, Go to ground transportation desk and use courtesy phone to arrange for pickup outside the terminal 800-258-3826.

FROM LAGUARDIA AIRPORT (LGA)

- Taxi metered fare $16–26 (plus tolls and gratuity).
- Airlink $20 one way fare, Shuttle bus from airport to Manhattan hotels (go to ground transportation desk in airport and see staff or use courtesy phone) 877-599-8200.
- New York Airport Service $17–23 one way, Look for bus stop sign that says New York Airport Service (buses run every 20–30 minutes). Take bus to Grand Central Station and transfer for drop off at hotel 718-875-8200.
- SuperShuttle $15–20 one way, Go to ground transportation desk and use courtesy phone to arrange for pickup outside the terminal 800-258-3826.

FROM NEWARK AIRPORT (EWR)

- Taxi metered fare $40–65 (plus tolls and gratuity).
- Airlink $20 one way fare, Shuttle bus from airport to Manhattan hotels (go to ground transportation desk in airport and see staff or use courtesy phone) 877-599-8200.
- Olympia Airport Express $11–16 one way, Go to ground transportation desk and buy a ticket and take bus to various locations in Manhattan.
- SuperShuttle $15–20 one way, Go to ground transportation desk and use courtesy phone to arrange for pickup outside the terminal 800-258-3826.

**FITNESS CENTER AND SPA**

The hotel offers a posh 8,000 sq. ft. Fitness by Precor® USA Center featuring premium Precor-developed strength, cardio and entertainment equipment. A complement of core training, balance equipment and stretch accessories rounds out the performance-enhancement offerings including Bosu balance trainers, medicine and stability balls, resistance bands, and exercise tubing and weighted body bars. Guests enjoy 24-hour access to the facility, with personal trainers available during regular business hours. The full service spa is also available to meet any of your needs while staying at the Hilton New York.

**HOTEL INFORMATION/RESERVATIONS**

Hilton New York
1335 Avenue of the Americas
New York, NY 10019
212-586-7000
FAX: 212-315-1374

The Hilton New York is a sophisticated hotel conveniently located in the midst of business and media centers in New York City, at West 53rd Street and Avenue of the Americas (Sixth Avenue).

The Hilton New York hotel is just moments from such famous landmarks as Radio City Music Hall, Museum of Modern Art (MOMA), Fifth Avenue shopping, Central Park, Rockefeller Center, Carnegie Hall, Lincoln Center, Broadway and Times Square.

Hilton New York hotel guestrooms are spacious and stylish with a comfortable work area, high-speed Internet access (wired and wireless), multiple-line phones, voicemail and data port, alarm clock radio with MP3 connection and complimentary newspaper Monday through Friday. Luxurious marble baths and hair dryers are also provided.

Sleeping room rates have been reserved for attendees at a conference rate of $289 single/double occupancy in a standard room. This reduced rate is available on a first come, first served basis until April 3, 2009. Reservation requests received after the cut-off date of April 3, 2009 will be based on availability at the Hotel’s prevailing rates, therefore we encourage you to make your reservations early. To reserve a room at the group rate, contact the hotel directly by calling their reservation line at 212-586-7000. **Please be sure to reference the American Association for the Treatment of Opioid Dependence or AATOD National Conference.** Reservations can also be made on-line through the AATOD website by clicking on the appropriate Hotel Reservations Link.

The Hilton New York is a sophisticated hotel conveniently located in the midst of business and media centers in New York City, at West 53rd Street and Avenue of the Americas (Sixth Avenue).

The Hilton New York hotel is just moments from such famous landmarks as Radio City Music Hall, Museum of Modern Art (MOMA), Fifth Avenue shopping, Central Park, Rockefeller Center, Carnegie Hall, Lincoln Center, Broadway and Times Square.

Hilton New York hotel guestrooms are spacious and stylish with a comfortable work area, high-speed Internet access (wired and wireless), multiple-line phones, voicemail and data port, alarm clock radio with MP3 connection and complimentary newspaper Monday through Friday. Luxurious marble baths and hair dryers are also provided.

Sleeping room rates have been reserved for attendees at a conference rate of $289 single/double occupancy in a standard room. This reduced rate is available on a first come, first served basis until April 3, 2009. Reservation requests received after the cut-off date of April 3, 2009 will be based on availability at the Hotel’s prevailing rates, therefore we encourage you to make your reservations early. To reserve a room at the group rate, contact the hotel directly by calling their reservation line at 212-586-7000. **Please be sure to reference the American Association for the Treatment of Opioid Dependence or AATOD National Conference.** Reservations can also be made on-line through the AATOD website by clicking on the appropriate Hotel Reservations Link.

**FITNESS CENTER AND SPA**

The hotel offers a posh 8,000 sq. ft. Fitness by Precor® USA Center featuring premium Precor-developed strength, cardio and entertainment equipment. A complement of core training, balance equipment and stretch accessories rounds out the performance-enhancement offerings including Bosu balance trainers, medicine and stability balls, resistance bands, and exercise tubing and weighted body bars. Guests enjoy 24-hour access to the facility, with personal trainers available during regular business hours. The full service spa is also available to meet any of your needs while staying at the Hilton New York.
Staying at the host hotel of the 2009 AATOD National Conference the Hilton New York, you might feel like you are in the center of the universe, with many of New York City’s vibrant cultural attractions only a short walk away.

Explore some of the brightest stars in the Theatre District only 4 to 10 blocks away. Over 20 Playhouses to choose from; Wicked, The Lion King, Hairspray, Phantom of the Opera, Jersey Boys and the newest Tony® Award winning Best Musical – In the Heights. www.PlayBill.com will keep you in the know and offer a ticket discount if one is available.

Just across the street Japanese architect Yoshio Taniguchi has demonstrated that architectural expression and the proper environment for looking at art can be brilliantly intertwined at an expanded MoMA - The Museum of Modern Art. With three dining options Café 2, Terrace 5 and The Modern featuring a dining room that overlooks The Abby Aldrich Rockefeller Sculpture Garden you can experience the art while being deliciously inspired by celebrated Chef Gabriel Kreuther French enthused cuisine. www.MoMa.org for current exhibits and reservations.

Whether it is cool blues, hot jazz, rock & roll, or a Harlem gospel Sunday brunch B.B. King’s Club & Grill at Times Square the “Crossroads of the World,” will fit the bill. Carnegie Hall or Carnegie Deli, world renowned classical music to sooth the soul and piled high corned beef and pastrami sandwiches to tickle your taste buds topped off with New York Cheesecake make walking 3 blocks in either direction an affair to remember. www.nycvisit.org

However far you walk, train or cab it from our host hotel don’t miss this unique opportunity to experience New York City guided by Your Hospitality Committee. Respectfully submitted by Haynes, the 2009 AATOD Hospitality Chair.
CONFERENCE REGISTRATION

Registration for the American Association for the Treatment of Opioid Dependence, Inc. (AATOD) annual conference can be done on-line by visiting the AATOD website at www.aatod.org or by completing the registration form on the inside back cover and faxing it to 856-423-3420 or by mailing it to:

AATOD 2009 National Conference Registration
c/o Talley Management Group, Inc.
19 Mantua Road
Mt. Royal, New Jersey 08061

If faxing your registration, DO NOT mail the original form, doing so may result in duplicate charges to your credit card! Should you have any questions regarding conference registration please call 856-423-3091.

CONTINUING EDUCATION CREDITS

- AATOD, Provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB).
- AATOD is an approved provider through the National Association of Alcoholism and Drug Abuse Counselors (NAADAC), Provider #000218.
- The New York State Office of Alcoholism and Substance Abuse Services’ (OASAS) recognizes the approval by NAADAC and, as such, all relevant/training will be acceptable for CASAC, CPP and/or GPS initial credentialing and/or renewal clock hours.
- This continuing nursing education activity has been submitted to the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
- Application to award Continuing Education hours (CEHs) also will be submitted to the National Board of Certified Counselors (NBCC)
Registration Information & Fees

HOW TO REGISTER:
Registration can be made on-line at www.AATOD.org and clicking the ON-LINE REGISTRATION LINK or by completing the Early Registration Form, pages 11 and 12, and mailing or faxing to the address provided.

<table>
<thead>
<tr>
<th>FULL CONFERENCE REGISTRATION*</th>
<th>1 PERSON FROM AN AGENCY</th>
<th>2 OR MORE FROM AN AGENCY, EACH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>August 1, 2008 – March 13, 2009</td>
<td>$500.00</td>
<td>$465.00</td>
</tr>
<tr>
<td>On-Site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>April 25, 2009</td>
<td>$560.00</td>
<td>No Group Discount Applies</td>
</tr>
</tbody>
</table>

* Includes: Admission to Pre-Conference Sessions (excluding Clinicians Course), Welcome Reception, all Plenary Sessions, Workshops, daily continental breakfast, refreshment breaks, and Awards Banquet.

There can be no conference registration fee splitting. Only one discount per conference participant is allowed, including the presenter's discount.

Group Discounts do not apply for the following categories:

**Single Day Registration**
(Does NOT include Awards Banquet) ........................................ $ 230.00

**Clinicians Course**
(Includes Welcome Reception) ............................................... $ 150.00

**Additional Awards Banquet Tickets**
(Must purchase on site) ....................................................... $ 75.00

**Additional Welcome Reception Tickets**
(Must purchase on site) ....................................................... $ 30.00

**CME / CEU FEES** *(These fees are not included in full conference registration fee)*
- Physicians / Physician Assistants / Pharmacists ........................................ $ 45.00
- Nurses / Social Workers / Psychologists ................................................. $ 35.00
- Counselors ....................................................................................... $ 25.00

Special Needs
The American Association for the Treatment of Opioid Dependence, Inc. wishes to take steps to ensure that no person with disabilities is excluded, denied services, segregated or otherwise treated differently than other individuals because of the absence of auxiliary aids and services. If you require any auxiliary aids or services identified in the Americans with Disabilities Act, please indicate so on your registration form.

STANDARD REGISTRATION ENDS MARCH 13, 2009
NATIONAL CONFERENCE  Treatment & Recovery: People & Outcomes
APRIL 25 - 29, 2009  HILTON NEW YORK

Use one form for each registrant. Photocopies of the form are acceptable. Please print clearly or type or you can register on-line at WWW.AATOD.ORG and click on the ON-LINE REGISTRATION LINK.

CONTACT INFORMATION: (please print)

First (Given) Name  Middle Initial  Last (Family) Name  Name on Badge

Degree  Affiliation (Employer)  Position/Title

Business Address  City  State/Province  Country  Zip Code

Business Telephone  Fax Number  E-Mail Address

PLEASE CHECK ONLY THE PROFESSIONAL DESIGNATION THAT APPLIES:
☐ Clinical / Medical  ☐ Funding / Evaluation  ☐ Research  ☐ Counseling  ☐ Administrative / Management  ☐ Policy  ☐ Other (Please Specify)

FULL CONFERENCE REGISTRATION:
Includes Welcome Reception and Awards Banquet:

(A) August 1, 2008 – March 13, 2009  Fee enclosed
☐ One person from an agency  . . . . $500  $____
☐ Two or more from an agency, each  . . . . $485  $____
☐ Single Day (specify day below) . . . . $230  $____
  ☐ Sunday
  ☐ Monday
  ☐ Tuesday (Does not include Awards Banquet)
  ☐ Wednesday
☐ Yes, I will be attending the Welcome Reception
☐ No, I will not attend the Welcome Reception
☐ Yes, I will be attending the Awards Banquet
☐ No, I will not attend the Awards Banquet
☐ Clinicians Course . . . . . . . . . . . . . . . . . . . . . . . . . . . $150  $____

CME/CEU FEES (NOT INCLUDED IN CONFERENCE REGISTRATION FEE)

Please indicate the type of continuing education units you intend to seek:
☐ Physicians  ☐ Physician Assistants  ☐ Pharmacists  . . . . $45  $____
☐ Nurses  ☐ Social Workers  ☐ Psychologists  . . . . $35  $____
☐ Counselors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $25  $____

TOTAL FEES $____

Please Note: Guest tickets for the Welcome Reception may be purchased on-site for $30.00. guest Tickets for the Awards Banquet may be purchased on-site for $75.00

Register for the conference on-line at www.aatod.org or mail or fax the Registration form with your payment in full to:

AATOD 2009 National Conference Registration
19 Mantua Road
Mt. Royal, New Jersey 08061
FAX: 856-423-3420

Please indicate any special assistance required:

____________________________________________________________
____________________________________________________________
____________________________________________________________

PAYMENT INFORMATION:
☐ I wish to pay my fees by CREDIT CARD
  Please note this charge will appear on your statement as
  “AATOD Conference Registration”
☐ Visa (13-16 digits)  ☐ MasterCard (16 digits)  ☐ American Express (15 digits)

ACCOUNT NUMBER

EXPIRATION DATE (mm/yy)

TOTAL FEES TO BE CHARGED $____

Cardholder (name as it appears on card): ____________________________

Cardholder’s Signature ____________________________

Registrations paid by credit card may be faxed to 856-423-3420. Please keep a copy of your fax confirmation for your record. If faxing, DO NOT mail the original form, doing so may result in duplicate charges to your credit card! *AATOD reserves the right to charge the correct amount if different from the total above.

Enclosed is payment by CHECK payable to the American Association for the Treatment of Opioid Dependence Inc.

To assure prompt processing of your registration, please be sure to remit your check in U.S. dollars and issued by a U.S. correspondent bank. Please check with your local bank before processing payment. Each registrant is responsible for any and all bank charges. A $50.00 processing fee will be charged for checks returned unpaid.

AATOD does not accept purchase orders as a form of payment.

AATOD 2009 National Conference Registration
19 Mantua Road
Mt. Royal, New Jersey 08061
FAX: 856-423-3420

CANCELLATION POLICY
If you must cancel your registration, the American Association for the Treatment of Opioid Dependence, Inc. Registration Department must receive all requests in writing no later than March 13, 2009. All fees paid will be returned less a $50.00 processing fee. THERE WILL BE NO REFUNDS AFTER THE MARCH 13TH DEADLINE.

REPLACEMENT POLICY
Replacements will only be processed when requests are received in writing prior to March 13, 2009. There will be NO replacements after that date.

Participation in this conference assumes knowledge and authorization of audio and/or video recording of portions of this conference. Registration will be confirmed in writing within two weeks of receipt of payment. If you do not receive confirmation by that time, please call 856-423-3091.
“The Premier Training Event for the Treatment of Opioid Dependence.”

new york city
2009

19 Mantua Road
Mt. Royal, New Jersey 08061

www.aatod.org

NATIONAL CONFERENCE
APRIL 25 - 29, 2009  HILTON NEW YORK

Conference Registration